American journal of clinical oncology
-
Am. J. Clin. Oncol. · Feb 2008
Randomized Controlled Trial Comparative StudyThere is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapy.
We have analyzed biochemical control versus multiple dosimetric parameters for a relatively homogeneous group of low-risk patients treated with I-125 or Pd-103. ⋯ Our demonstration of some predictive value of nearly all dosimetric parameters is in contrast to the impression one is left with from prior reports, which explicitly or implicitly portray a unique role for D90 or V100. We think that it is important for clinical investigators to look at other dosimetric parameters as part of ongoing clinical investigations because it is likely that dosimetric guidelines can be refined to improve our ability to rate implant quality.